Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 Recruiting
115 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Phase 2 Recruiting
108 enrolled
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Phase 2 Recruiting
20 enrolled
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Phase 2 Recruiting
105 enrolled
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Phase 2 Recruiting
40 enrolled
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Phase 2 Recruiting
51 enrolled
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Phase 2 Recruiting
68 enrolled
TAYLOR
Phase 2 Recruiting
200 enrolled
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Phase 2 Recruiting
43 enrolled
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Phase 2 Recruiting
25 enrolled
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 Recruiting
94 enrolled
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Phase 2 Recruiting
30 enrolled
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Phase 2 Recruiting
51 enrolled
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Phase 2 Recruiting
50 enrolled
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Phase 2 Recruiting
38 enrolled
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Phase 2 Recruiting
36 enrolled
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
Phase 2 Recruiting
240 enrolled
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Phase 2 Recruiting
62 enrolled
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Phase 2 Recruiting
10 enrolled
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Phase 2 Recruiting
280 enrolled
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
Phase 2 Recruiting
46 enrolled
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 Recruiting
45 enrolled
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Phase 2 Recruiting
60 enrolled
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Phase 2 Recruiting
98 enrolled
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Phase 2 Recruiting
40 enrolled
CNN-BC
Phase 2 Recruiting
32 enrolled
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2 Recruiting
36 enrolled
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 Recruiting
117 enrolled
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Phase 2 Recruiting
68 enrolled
NEOVADE
Phase 2 Recruiting
32 enrolled
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Phase 2 Recruiting
116 enrolled
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Phase 2 Recruiting
338 enrolled
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
Phase 2 Recruiting
30 enrolled
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Phase 2 Recruiting
48 enrolled
RCT-PAAG
Phase 2 Recruiting
177 enrolled
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2 Recruiting
140 enrolled
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 Recruiting
30 enrolled